Entera Bio Ltd. Aktie News

This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities

FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613

Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below.

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause

First-time presentation examining bone outcomes in early postmenopausal women First-time presentation examining bone outcomes in early postmenopausal women

Entera Bio (ENTX 1.11%), a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most notable news was a better-than-expected GAAP earnings per share of $0.06, compared to Wall Street estimates for a GAAP loss of $(0.11).